CAS: 209410-46-8; 5-(2,6-Dichlorophenyl)-2-((2,4-Difluorophenyl)Thio)-6H-Pyrimido[1,6-B]Pyridazin-6-One

该化合物是合成有机化合物,其特点是复杂的循环结构,具有合成有机化合物,其特征是:一种火水化合物和pyridazine核心,有助于其潜在的生物活动;二氯苯和二氟苯组的存在表明,它具有重大的卤化作用,能够增强对化合物与生物目标的相互作用产生影响.硫醚联系在结构中引入硫磺,有可能影响其再活动性和溶解性.这种化合物可能表现出药用特性,从而引起对医药化学的兴趣,特别是在开发新的治疗剂方面.其具体特性,例如熔点,溶性,溶性以及光谱数据,通常通过实验方法来确定.

结构式图片

欧盟法规

C&L通报

合成工艺路线路线简述

    2,6-二氯苯乙腈置于peppsitm-Ipr 硫酸,Potassium Tert-Butylate,Sodium T-Butanolate体系中,用 甲苯 用作溶剂,化学反应 23.0H,反应生成5-(2,6-二氯苯基)-2-((2,4-二氟苯基)硫基)-6H-嘧啶并[1,6-B]哒嗪-6-酮
    参考文献:Rapid Synthesis Of Vx-745: P38 Map Kinase Inhibition In Werner Syndrome Cells
    标题:Rapid Synthesis Of Vx-745: P38 Map Kinase Inhibition In Werner Syndrome Cells
    摘要:The P38 Mitogen-Activated Protein Kinase Inhibitor Vx-745 Is Prepared Rapidly And Efficiently In A Four-Step Sequence Using A Combination Of Conductive Heating And Microwave-Niediated Steps. Its Inhibitory Activity Was Confirmed In Htert Immortalized Hca2 And Ws Dermal Fibroblasts At 0.5-1.0 Mu M Concentration By Elisa And Immunoblot Assay,And Displays Excellent Kinase Selectivity Over The Related Stress-Activated Kinase Jnk. (C) 2007 Elsevier Ltd. All Rights Reserved.
    Doi:10.1016/j.Bmcl.2007.07.016

    海关参考信息

    专利信息


    专利号:US-12383499-B2
    优先权日:2018-01-01
    标题:Scale up synthesis of silicasome nanocarriers
    发明人:NEL ANDRE E; MENG HUAN; LIU XIANGSHENG
    权利人:UNIV CALIFORNIA
    摘要:In order to facilitate the approval and commercialization of silicasome drug delivery systems (e.g. irinotecan silicasomes) it is necessary to scale up synthesis of the drug-loaded silicasomes. In this regard, it was discovered that the synthesis protocols used for laboratory synthesis of drug-loaded silicasomes (e.g., 500 mg/batch) do not scale to large scale silicasome production, because the resulting products were too heterogeneous for use as pharmaceuticals. Accordingly, new methods are provided herein that effectively afford the large-scale production of mesoporous silica nanoparticles (MSNPs) and lipid bilayer coated MSNPs (silicasomes).

    专利号:US-12006337-B2
    优先权日:2018-05-30
    标题:Mitogen-activated protein kinase inhibitors, methods of making, and methods of use thereof
    发明人:HOLTZMAN MICHAEL J; ROMERO ARTHUR G; GEROVAC BENJAMIN J; HAN ZHENFU; KEELER SHAMUS P; WU KANGYUN; ZHANG YONG
    权利人:WASHINGTON UNIVERSITY ST LOUIS
    摘要:Compounds that inhibit mitogen-activated protein kinases (MAPKs) are disclosed. Some inhibitor compounds specifically target a single MAPK such as MAPK13, while others target multiple MAPKs such as MAPK13 and MAPK12. The compounds can be used therapeutically for a variety of diseases, including cancer and respiratory diseases. Methods of synthesis of the compounds are also disclosed.

    专利号:US-2025289827-A1
    优先权日:2022-12-02
    标 题:Morphic forms of a mutant braf degrader and methods of manufacture thereof
    发明人:YU ROBERT T; HE MINSHENG; SCHNADERBECK MATTHEW J; KREGER BRIDGET; POLLOCK ROY MACFARLANE; JIANG SIYI; LI MEIQI; CHEN BOLU; LU JIANNAN
    权利人:C4 THERAPEUTICS INC
    摘要:Advantageous isolated morphic forms of (3R)-3-[6-[2-cyano-3-[[ethyl(methyl)sulfamoyl]amino]-6-fluorophenoxy]-4-oxoquinazolin-3-yl]-8-[2-[1-[3-(2,4-dioxo-1,3-diazinan-1-yl)-5-fluoro-1-methylindazol-6-yl]-4-hydroxypiperidin-4-yl]acetyl]-1-oxa-8-azaspiro[4.5]decane (Compound 1), which is a mutant BRAF degrader, and methods to prepare Compound 1 morphic forms for therapeutic applications are provided in the invention. The invention also provides improved methods for the synthesis of Compound 1, new pharmaceutical compositions comprising Compound 1, and new uses of Compound 1.

    专利号:US-2022143183-A1
    优先权日:2019-02-23
    标题:Photoswitchable protacs and synthesis and uses thereof
    发明人:TRAUNER DIRK; REYNDERS MARTIN; MATSUURA BRYAN; BEROUTI MARLEEN; PAGANO MICHELE
    权利人:UNIV NEW YORK
    摘要:Provided are compounds, which may be referred to as PHOTACs (photoswitchable proteolysis targeting chimeras), and compositions, kits, and methods of making and using PHOTACs. PHOTACs have one or more E3 ligase ligand(s), one or more photoswitchable group(s), optionally, one or more linker(s), and one or more ligand(s) for a target protein. PHOTACs may be suitable for use in methods to treat diseases, such as, for example, cancer. PHOTACs may also be suitable for use in methods to induce selective degradation of a target protein.

    专利号:CN-108821968-A
    优先权日:2018-06-28
    标题:Preparation method of in-situ acid resin catalyzed synthesis of higher carbon alkyl acrylate

    专利号:CN-111575006-A
    优先权日:2020-03-11
    标 题 :A kind of alloy quantum dot synthesis method
    上海艾黎化学科技有限公司
    ⚠️ 未注册 · 未认证企业
    ⚠️ 该商家尚未完成注册及企业认证,请用户仔细辨别,谨慎交易。
    数据来源于公开网络搜索,平台未作核实,请自行辨别。
    🏢敬请 企业认领
    🏬开设公司展台
    📢获取免费会员权益
    🎖️点亮专属注册企业标签
    📇展现公司完整信息 样本查看立即注册认领 →
    电话:021-33820069👤
    ⚠️参考联系方式
    邮件:yunmeng619@163.com
    销售经理: 林经理
    联系电话:021-33820069
    手机号码: 138 1738 3139
    传真号码: 021-33827747
    QQ号:287705286
    🆔 联系时候可告知是从"百琢研"平台获取的信息.
    ⚠️ 声明: 该企业未认证、未认领,请自行辨别信息的真实性和可靠性。咨询或交易时请注意风险评估与信息核实,百琢研不参与任何交易。企业认领注册入口→

    浦东大道2742号1701
    ⚠️ 未注册 · 未认证企业
    注册入口 声明: 数据来源:本内容基于各搜索引擎等公开数据整理,仅作展示用。请自行辨别 📄若企业需抹除相关内容或, 请联系方我们,我们即刻栓除。
    上海舒盟医药科技有限公司
    ⚠️ 未注册 · 未认证企业
    ⚠️ 该商家尚未完成注册及企业认证,请用户仔细辨别,谨慎交易。
    数据来源于公开网络搜索,平台未作核实,请自行辨别。
    🏢敬请 企业认领
    🏬开设公司展台
    📢获取免费会员权益
    🎖️点亮专属注册企业标签
    📇展现公司完整信息 样本查看立即注册认领 →
    网址: http://www.amaspharm.com
    电话: 021-54540637 18621091017👤
    📞上海舒盟医药科技有限公司 ⚠️参考联系方式

    销售电话:021-54540637 18621091017
    邮箱:sales@amaspharm.com
    🆔 联系时候可告知是从"百琢研"平台获取的信息.
    ⚠️ 声明: 该企业未认证、未认领,请自行辨别信息的真实性和可靠性。咨询或交易时请注意风险评估与信息核实,百琢研不参与任何交易。企业认领注册入口→

    ⚠️ 未注册 · 未认证企业
    注册入口 备注: 📌 数据来源说明:本展台内容基于各搜索引擎等公开数据整理,仅作展示用途。请用户自行辨别 ✉️ 若企业需抹除展台内容或有异议, 请通过页面底部联系方式告知我们,我们会尽快处理。
    上海昶衍化工科技有限公司
    小微企业
    信用代码: 91310116588693169L法定代表人:杨永宁
    注册资本:50万(元)企业类型:有限责任公司(自然人投资或控股)
    成立日期:2012-01-05登记机关:金山区市场监督管理局
    注册地址: 上海市金山区枫泾镇环东一路65弄2号2107室
    从事化工科技领域内的技术开发、技术服务、技术咨询,化工原料及产品(除危险化学品、监控化学品、烟花爆竹、民用爆炸物品、易制毒化学品),实验室设备,金属材料,包装材料销售,从事货物进出口及技术进出口业务,贸易经纪与代理。
    免费会员展台
    https://www.changyanchem.cn
    企业联系电话:021-2024 2659👤
    上海昶衍化工科技有限公司
    销售经理: 王经理
    手机:18930833303
    客服热线:021-2024 2659
    传真:021-2024 2659
    微信:18930833303
    E-mail:Sales@changyanchem.cn
    QQ: 2314616215
    ⚠️ 声明: 咨询或交易时请注意风险评估和信息核实,百琢研不参与任何交易。

    上海市金山区枫泾镇环东一路65弄2号2107室
    常规和库存产品*产品总量: 1129

    平台资质认证✓营业执照✓
    209410-46-8
    VX-745
    其他备注:
    主营化学品定制为主,集药物中间体以及活性分子研发,生产,销售和贸易为一体
    第 1 / 1 页
    现货

    供应商参考报价(招募中)

    品牌试剂参考报价(招募中)

    📌 第三方产品分析报告

    ✅ COA系统入驻 | 共享模式

    主要参考文献


    1: Davis T, Brook AJ, Rokicki MJ, Bagley MC, Kipling D. Evaluating the Role of p38 MAPK in the Accelerated Cell Senescence of Werner Syndrome Fibroblasts. Pharmaceuticals (Basel). 2016 Apr 28;9(2). pii: E23. doi: 10.3390/ph9020023. doi: 10.3233/JAD-150277. doi: 10.1016/j.ejpb.2015.03.017. Epub 2015 Mar 30. doi: 10.1128/MCB.01691-12. Epub 2013 Aug 26.
    5: Tsai YR, Wang YJ, Lee MR, Hsu MF, Wang JP. p38 Mitogen-activated protein kinase and extracellular signal-regulated kinase signaling pathways are not essential regulators of formyl peptide-stimulated p47(phox) activation in neutrophils. Eur J Pharmacol. 2013 Feb 15;701(1-3):96-105. doi: 10.1016/j.ejphar.2013.01.003. Epub 2013 Jan 21. doi: 10.1107/S090744491201997X. Epub 2012 Jul 17. doi: 10.1021/ml2001455. eCollection 2011 Oct 13.
    8: Selness SR, Boehm TL, Walker JK, Devadas B, Durley RC, Kurumbail R, Shieh H, Xing L, Hepperle M, Rucker PV, Jerome KD, Benson AG, Marrufo LD, Madsen HM, Hitchcock J, Owen TJ, Christie L, Promo MA, Hickory BS, Alvira E, Naing W, Blevis-Bal R, Devraj RV, Messing D, Schindler JF, Hirsch J, Saabye M, Bonar S, Webb E, Anderson G, Monahan JB. Design, synthesis and activity of a potent, selective series of N-aryl pyridinone inhibitors of p38 kinase. Bioorg Med Chem Lett. 2011 Jul 1;21(13):4059-65. doi: 10.1016/j.bmcl.2011.04.120. Epub 2011 May 13. doi: 10.1016/j.chembiol.2011.01.015. doi: 10.4155/fmc.10.217. doi: 10.1016/j.intimp.2010.01.007. Epub 2010 Jan 20. doi: 10.1021/jo9017155. doi: 10.1002/art.24264. doi: 10.1186/1476-9255-5-22.
    📝 需求与反馈
    尽可能描述清楚需求与问题信息
    ×

    通知